This paper included information on a single case report of a patient with chronic inflammatory demyelinating polyneuropathy (CIDP). The authors noted that the patient was receiving subcutaneous immunoglobin (SCIG) who had his dose fine-tuned from 24 g per week to 28 g per week. According to their paper, the patient showed dramatic improvement in measures of hand grip (13% to 25%) and dorsiflexion (73% to 278%). They also reported significant improvements in latencies, motor amplitudes, and conduction velocities on follow-up. “Ongoing surveillance of CIDP patients receiving SCIG therapy is […] necessary to ensure therapeutic optimization,” they said. “Furthermore, predictive modelling of IgG dosing in neurologic indications, such as CIDP, fails to recognize the distinct pathophysiologic variability in these patients.”

This article was originally published here